Arbutus Biopharma Corp. Files 2023 Annual Report on Form 10-K
Ticker: ABUS · Form: 10-K · Filed: 2024-03-05T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, Arbutus Biopharma, Annual Report, Financials, Pharmaceuticals
TL;DR
<b>Arbutus Biopharma Corp. has filed its annual 10-K report for the fiscal year ending December 31, 2023.</b>
AI Summary
Arbutus Biopharma Corp (ABUS) filed a Annual Report (10-K) with the SEC on March 5, 2024. Arbutus Biopharma Corp. filed its 2023 Form 10-K on March 5, 2024. The company's fiscal year ends on December 31st. Arbutus Biopharma Corp. was formerly known as TEKMIRA PHARMACEUTICALS Corp. The company's business address is 701 VETERANS CIRCLE, WARMINSTER, PA 18974. The filing includes financial data for the fiscal year ended December 31, 2023.
Why It Matters
For investors and stakeholders tracking Arbutus Biopharma Corp, this filing contains several important signals. This filing provides a comprehensive overview of the company's financial performance and operational status for the past fiscal year. Investors and stakeholders can use this report to assess the company's financial health, strategic direction, and potential risks.
Risk Assessment
Risk Level: medium — Arbutus Biopharma Corp shows moderate risk based on this filing. The company's financial statements and risk factors require careful review due to the nature of the pharmaceutical industry and potential litigation or regulatory challenges.
Analyst Insight
Review the detailed financial statements and risk factor disclosures in the 10-K to understand Arbutus Biopharma's current financial position and future outlook.
Key Numbers
- 2023-12-31 — Fiscal Year End (Conformed Period of Report)
- 2024-03-05 — Filing Date (Filed as of Date)
- 001-34949 — SEC File Number (SEC File Number)
Key Players & Entities
- Arbutus Biopharma Corp. (company) — Filer name
- TEKMIRA PHARMACEUTICALS Corp (company) — Former company name
- 0001447028 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 701 VETERANS CIRCLE, WARMINSTER, PA 18974 (company) — Business Address
- 604-419-3200 (company) — Business Phone
- Genevant Sciences Corporation (company) — Subsidiary
FAQ
When did Arbutus Biopharma Corp file this 10-K?
Arbutus Biopharma Corp filed this Annual Report (10-K) with the SEC on March 5, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Arbutus Biopharma Corp (ABUS).
Where can I read the original 10-K filing from Arbutus Biopharma Corp?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Arbutus Biopharma Corp.
What are the key takeaways from Arbutus Biopharma Corp's 10-K?
Arbutus Biopharma Corp filed this 10-K on March 5, 2024. Key takeaways: Arbutus Biopharma Corp. filed its 2023 Form 10-K on March 5, 2024.. The company's fiscal year ends on December 31st.. Arbutus Biopharma Corp. was formerly known as TEKMIRA PHARMACEUTICALS Corp..
Is Arbutus Biopharma Corp a risky investment based on this filing?
Based on this 10-K, Arbutus Biopharma Corp presents a moderate-risk profile. The company's financial statements and risk factors require careful review due to the nature of the pharmaceutical industry and potential litigation or regulatory challenges.
What should investors do after reading Arbutus Biopharma Corp's 10-K?
Review the detailed financial statements and risk factor disclosures in the 10-K to understand Arbutus Biopharma's current financial position and future outlook. The overall sentiment from this filing is neutral.
How does Arbutus Biopharma Corp compare to its industry peers?
Arbutus Biopharma Corp. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of treatments for liver disease.
Are there regulatory concerns for Arbutus Biopharma Corp?
The company is subject to regulations by the Securities and Exchange Commission (SEC) for its public filings, including the annual 10-K report.
Industry Context
Arbutus Biopharma Corp. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of treatments for liver disease.
Regulatory Implications
The company is subject to regulations by the Securities and Exchange Commission (SEC) for its public filings, including the annual 10-K report.
What Investors Should Do
- Analyze the financial statements for revenue, expenses, and net income.
- Review the Management's Discussion and Analysis of Financial Condition and Results of Operations for insights into business performance.
- Examine the Risk Factors section for potential challenges and uncertainties facing the company.
Key Dates
- 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
- 2024-03-05: Filing Date — Date the 10-K report was officially filed with the SEC.
Year-Over-Year Comparison
This is the initial filing data extracted for the 2023 10-K. Comparative data from previous filings would be needed for a full 'vs last filing' analysis.
From the Filing
0001447028-24-000035.txt : 20240305 0001447028-24-000035.hdr.sgml : 20240305 20240305164849 ACCESSION NUMBER: 0001447028-24-000035 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 125 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 24721612 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 10-K 1 abus-20231231.htm 10-K abus-20231231 false 0001447028 2023 FY 0.3333 0.3333 0.3333 0001447028 2023-01-01 2023-12-31 0001447028 2023-06-30 iso4217:USD 0001447028 2024-03-01 xbrli:shares 0001447028 2023-12-31 0001447028 abus:OMERSMember 2019-07-02 2022-12-31 0001447028 2022-12-31 0001447028 abus:CollaborationAndContractsMember 2023-01-01 2023-12-31 0001447028 abus:CollaborationAndContractsMember 2022-01-01 2022-12-31 0001447028 abus:NonCashRoyaltyMember 2023-01-01 2023-12-31 0001447028 abus:NonCashRoyaltyMember 2022-01-01 2022-12-31 0001447028 2022-01-01 2022-12-31 iso4217:USD xbrli:shares 0001447028 us-gaap:CommonStockMember 2021-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001447028 us-gaap:RetainedEarningsMember 2021-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001447028 2021-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001447028 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001447028 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001447028 us-gaap:CommonStockMember 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001447028 us-gaap:RetainedEarningsMember 2022-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001447028 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001447028 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001447028 us-gaap:CommonStockMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001447028 us-gaap:RetainedEarningsMember 2023-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 abus:subsidiary 0001447028 abus:GenevantSciencesCorporationMember 2023-12-31 xbrli:pure 0001447028 abus:LaboratoryEquipmentMember 2023-12-31 0001447028 us-gaap:ComputerEquipmentMember srt:MinimumMember 2023-12-31 0001447028 us-gaap:ComputerEquipmentMember srt:MaximumMember 2023-12-31 0001447028 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001447028 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001447028 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001447028 abus:DirectorsAndExecutivesMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 abus:segment 0001447028 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001447028 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001447028 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001447028 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001447028 us-gaap:FairValueInputsLevel1Member us-gaap:Fa